Literature DB >> 10554810

Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.

A R Pettitt1, A R Clarke, J C Cawley, S D Griffiths.   

Abstract

To resolve the controversy concerning the role of p53 in the killing of resting lymphocytes by purine nucleoside analogues, we examined the cytotoxic effects of chlorodeoxyadenosine, fludarabine and deoxycoformycin (plus deoxyadenosine) on unstimulated spleen cells from p53-knockout versus wild-type mice. p53-knockout cells were more resistant to all three nucleosides than were wild-type cells. However, substantial killing still occurred in the absence of p53, indicating that purine analogues can kill resting lymphocytes by both p53-dependent and -independent mechanisms. We suggest that these results are relevant to chronic lymphoid malignancies, and that characterization of the p53-independent component of nucleoside action may indicate potential ways of overcoming therapeutic resistance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554810     DOI: 10.1046/j.1365-2141.1999.01448.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.

Authors:  Paolo Strati; Michael J Keating; Susan M O'Brien; Alessandra Ferrajoli; Jan Burger; Stefan Faderl; Francesco Paolo Tambaro; Nitin Jain; William G Wierda
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

2.  Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells.

Authors:  Paula X Fernández-Calotti; Mónica Lopez-Guerra; Dolors Colomer; Marçal Pastor-Anglada
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

Review 3.  Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

Authors:  S A Johnson
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 4.  What is the best frontline therapy for patients with CLL and 17p deletion?

Authors:  Xavier C Badoux; Michael J Keating; William G Wierda
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

5.  Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria.

Authors:  I Marzo; P Pérez-Galán; P Giraldo; D Rubio-Félix; A Anel; J Naval
Journal:  Biochem J       Date:  2001-11-01       Impact factor: 3.857

6.  Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.

Authors:  Etienne Moussay; Valérie Palissot; Laurent Vallar; Hélène A Poirel; Thomas Wenner; Victoria El Khoury; Nasséra Aouali; Kris Van Moer; Bernadette Leners; François Bernardin; Arnaud Muller; Pascale Cornillet-Lefebvre; Alain Delmer; Caroline Duhem; Fernand Ries; Eric van Dyck; Guy Berchem
Journal:  Mol Cancer       Date:  2010-05-20       Impact factor: 27.401

7.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.

Authors:  Kensuke Kojima; Marina Konopleva; Teresa McQueen; Susan O'Brien; William Plunkett; Michael Andreeff
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

8.  Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.

Authors:  Lisa S Chen; William Plunkett; Varsha Gandhi
Journal:  Leuk Res       Date:  2008-04-22       Impact factor: 3.156

9.  Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.

Authors:  May Shawi; Tsz Wai Chu; Veronica Martinez-Marignac; Y Yu; Sergei M Gryaznov; James B Johnston; Susan P Lees-Miller; Sarit E Assouline; Chantal Autexier; Raquel Aloyz
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

Review 10.  New insights into the synergism of nucleoside analogs with radiotherapy.

Authors:  Michael W Lee; William B Parker; Bo Xu
Journal:  Radiat Oncol       Date:  2013-09-26       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.